Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Explore CAR-T · collection map

CAR-T · Evidence by disease

Evidence atlas: read the denominator before the headline

A curated primary-source map, not a pooled response estimate.

By Olga Goodman, MD · Original review: 25 September 2026 · Evidence updates: 13 November 2026

In this chapter
  1. 2022 · Initial refractory SLE series
  2. 2024 · Multidisease NEJM series
  3. 2026 · CASTLE
  4. 2025 · CD19 + BCMA co-infusion
  5. 2026 · ICG318 extended follow-up
  6. 2026 · COMPARE phase 1
  7. 2026 · Pediatric autologous series
  8. 2025 · Allogeneic YTS109
  9. 2026 · Skin-remodeling analysis
  10. 2025 · AAV report
  11. 2024 · Sjögren’s with lymphoma
  12. 2026 · Descartes-08 phase 2b
  13. 2025–26 · In vivo reports
  14. 2026 · TRITON
  15. 2026 · A-319
  16. CD19-BBz CAR-NK in refractory SLE

Studies are organized by disease, design and platform. This is not a systematic review or a meta-analysis. Cohorts may overlap across clinical, mechanistic and conference publications; the rows must not be added to estimate a unique treated population.

SLE · Uncontrolled case series

2022 · Initial refractory SLE series

Population: 5

All five met DORIS remission at 3 months; initial follow-up was short. [1]

Interpretation: Established human proof of concept; do not count early patients again when later overlapping series are summarized.

SLE / SSc / IIM · Uncontrolled case series

2024 · Multidisease NEJM series

Population: 15: 8 / 4 / 3

Median follow-up 15 months, range 4–29. Disease-specific improvement and immunosuppressive withdrawal were reported. [2]

Interpretation: Endpoints differed by disease; one grade-1 ICANS and pneumonia requiring hospitalization were reported.

SLE / SSc / IIM · Prospective phase 1/2 basket trial

2026 · CASTLE

Population: 24: 10 / 9 / 5

At 24 weeks: SLE DORIS 9/10; SSc no progression 9/9; IIM moderate/major response 4/5. All 24 were off glucocorticoids and other immunosuppression during the assessment period. [3]

Interpretation: No CRS above grade 2 or ICANS in this cohort; 15 serious adverse events were recorded. “22/24 endpoints met” is not “22/24 cured.”

SLE · Phase 1 dose escalation

2025 · CD19 + BCMA co-infusion

Population: 15

Evaluated two autologous products after lymphodepletion, with early clinical and safety endpoints. [7]

Interpretation: Separate-product co-infusion; no direct comparison proving superiority over single-target CAR-T.

SLE / lupus nephritis · Phase 1 follow-up correspondence

2026 · ICG318 extended follow-up

Population: 12

Reported stringent complete remission in 10/12. Median follow-up 30 months; maximum 67 months. [4]

Interpretation: Two patients had concomitant lymphoma; small uncontrolled cohort. Maximum follow-up must not be presented as the duration for every patient.

ACPA-positive RA · Phase 1 portion of phase 1/2 trial

2026 · COMPARE phase 1

Population: 6

Three achieved DAS28-CRP remission and ACR70; follow-up 36–52 weeks. [5]

Interpretation: All had grade-1/2 CRS; one reversible grade-3 transaminase DLT. No ICANS or serious adverse events reported in these six.

Childhood SLE / DM / SSc · Hospital-exemption case series

2026 · Pediatric autologous series

Population: 8: 4 / 3 / 1

Published clinical experience in severe treatment-refractory childhood disease. [6]

Interpretation: Not a randomized pediatric trial or a general approval for children; do not infer efficacy for all juvenile rheumatic disorders.

Severe SLE with nephritis · Phase 1 cohort

2025 · Allogeneic YTS109

Population: 5

Early human feasibility of a gene-edited donor-derived CD19-targeting STAR product. [8]

Interpretation: Distinct architecture; small cohort cannot resolve rejection, durability or uncommon toxicity.

Systemic sclerosis · Mechanistic tissue study

2026 · Skin-remodeling analysis

Population: Serial samples

Skin structural, fibroblast and vascular changes supported tissue-remodeling potential. [13]

Interpretation: Includes previously treated CASTLE/named-patient material; not a new independent randomized efficacy cohort.

ANCA-associated vasculitis · Human case report

2025 · AAV report

Population: 1

Reported anti-CD19 treatment with antibody seroconversion and marrow B-cell depletion. [14]

Interpretation: Case-level evidence; not a standard induction pathway or proof in all AAV phenotypes.

Sjögren’s / DLBCL · Human case report

2024 · Sjögren’s with lymphoma

Population: 1

Sjögren’s improvement was described during lymphoma-directed CAR-T treatment. [15]

Interpretation: Concurrent malignancy and its treatment substantially confound disease-specific conclusions.

Generalized myasthenia gravis · Randomized placebo-controlled trial

2026 · Descartes-08 phase 2b

Population: 36 randomized; 26 primary efficacy

The reported 3-month MGC response was 10/15 versus 3/11 in the primary efficacy population. [9]

Interpretation: Neurologic, not myositis, efficacy. The randomized and primary-efficacy denominators differ and require scrutiny.

SLE / neurologic autoimmunity · Early clinical correspondence

2025–26 · In vivo reports

Population: Small / heterogeneous

Human proof of concept has been reported for RNA/LNP SLE and lentiviral neurologic approaches. [11]

Interpretation: Different delivery systems and diseases; no automatic extrapolation to routine rheumatology care.

DM / antisynthetase syndrome · Registered randomized phase 2

2026 · TRITON

Population: Planned trial

A placebo-controlled Descartes-08 myositis protocol is registered. [31]

Interpretation: Study design is not an efficacy result; current enrollment must be confirmed with the site.

SLE · Phase 1 bispecific-antibody trial

2026 · A-319

Population: 12 in IV arm

A CD3×CD19 T-cell engager was evaluated with 52-week follow-up. [19]

Interpretation: Comparator landscape only: this is not CAR-T and not a CAR-T head-to-head trial.

For new data, preserve screened, enrolled, apheresed, manufactured, infused and evaluable denominators whenever available. Manufacturing failure, early withdrawal, missing assessments and rescue therapy all affect interpretation. Event-free nonprogression is not synonymous with remission; a laboratory response is not automatically an organ response.

E16 · Adjacent cellular platform · Primary research

CD19-BBz CAR-NK in refractory SLE

Design: phase 1, open-label dose escalation; 5 patients.

Main observation: 4/5 met DORIS remission at final follow-up, median 12 months.

Boundary: CAR-NK, not CAR-T; no controlled superiority comparison or inferred drug-free remission rate. [40]

RA · ACR Convergence 2026 abstract · COMPARE

November 2026 · COMPARE week-36 follow-up

Population: 6 patients already included in the published COMPARE phase 1 cohort; not an independent new cohort.

Four patients reached DAS28-CRP remission and ACR70 by week 36; this differs from remission at latest follow-up and should not be substituted for the published endpoint. ACR abstract.

Interpretation: Abstract-level longitudinal update, uncontrolled cohort; the timepoint, treatment exposure and flare history determine the interpretation.

Lupus nephritis / SSc · Company-reported ACR 2026 updates

November 2026 · Rese-cel organ-specific signals

Lupus nephritis: five of five participants who elected repeat biopsy had histologic response or remission and DORIS remission off immunomodulators. Systemic sclerosis: five of seven evaluated at one year met rCRISS-50. Cabaletta company report.

Interpretation: Different disease-specific endpoints and selected denominators, not a comparative treatment effect or evidence of universal organ reversal.

SLE / SSc / IIM · ACR Convergence 2026 relapse case series

November 2026 · Long-term relapses after CD19 CAR-T

Population: 50 recipients, including 28 SLE, 14 SSc and 8 inflammatory myopathy patients. Seven relapses were reported (1, 3 and 3 respectively), at a median of 18 months after infusion. ACR 2026 abstract.

Interpretation: Selected, heterogeneous single-center experience with at least six months of follow-up; not a general population estimate and not proof of a standard rescue treatment sequence.

Sources · 16

Source titles are shown in their original language.

[1] Primary research · 2022-09-15

Mackensen et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine.

Open original source ↗

[2] Primary research · 2024-02-21

Müller et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. NEJM.

Open original source ↗

[3] Primary research · 2026-01-07

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nature Medicine.

Open original source ↗

[4] Primary research · 2026-01-29

Hong et al. BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial. J Hematol Oncol.

Open original source ↗

[5] Primary research · 2026-08-27

Albach et al. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial. Nature Medicine.

Publisher abstract and publication metadata reviewed; no claim of full supplementary-data review.

Open original source ↗

[6] Primary research · 2026-02-05

Becilli et al. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases. Nature Medicine.

Publisher/PubMed abstract and metadata; detailed numerical efficacy extraction deliberately limited.

Open original source ↗

[7] Primary research · 2025-09-24

Feng et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory SLE: a phase 1 trial. Nature Medicine.

Primary abstract reviewed; two separately manufactured products, not a single dual-target construct.

Open original source ↗

[8] Primary research · 2025-08-27

Wang et al. Allogeneic CD19-targeting T cells for treatment-refractory SLE: a phase 1 trial. Nature Medicine.

YTS109 uses a synthetic TCR and antigen receptor (STAR); do not describe all engineered T-cell products as identical conventional CARs.

Open original source ↗

[9] Primary research · 2026-01-09

Vu et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine.

Open original source ↗

[11] Primary research · 2025-09-17

Wang et al. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. NEJM.

Primary correspondence/abstract; early human proof of concept, not confirmatory trial evidence.

Open original source ↗

[13] Primary research · 2026-05-23

Rius Rigau et al. Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells. Nature Communications.

Mechanistic tissue study; includes CASTLE/named-patient material, not wholly independent treatment cohort.

Open original source ↗

[14] Primary research · 2025-01-31

Minopoulou et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in bone marrow in therapy-refractory ANCA-associated vasculitis. Ann Rheum Dis.

Human case report; not a controlled vasculitis trial.

Open original source ↗

[15] Primary research · 2024

CAR T-cell therapy in a patient with Sjögren’s syndrome and diffuse large B-cell lymphoma. Primary report, PubMed 38173731.

Concurrent lymphoma materially limits inference about Sjögren’s-specific efficacy.

Open original source ↗

[19] Primary research · 2026-09-10

A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial. Nature Medicine.

A-319 is a bispecific antibody/T-cell engager, not CAR T-cell therapy.

Open original source ↗

[31] Trial-center registry record · 2026

UC Irvine clinical trial record. Descartes-08 in dermatomyositis and antisynthetase syndrome (TRITON), NCT07391605.

Protocol identity/design verified; live enrollment availability not independently confirmed with the site.

Open original source ↗

[40] Primary research · 2026-07-22

Zeng et al. Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med.

Primary abstract reviewed; August 14, 2026 issue. Five-patient phase 1 cohort; CAR-NK, not CAR-T.

Open original source ↗

Continue exploring

Back to top ↑

Personal educational publication; not a clinic portal or an offer to administer CAR-T. Any private expert opinion is separate from clinic care and accounts, paid directly and not billed to insurance.

Original educational content by Dr. Olga Goodman / Olga Goodman, MD. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: CAR-T